Hanaway 2008.

Methods	RCT
Participants	Setting: NS Country: USA Randomised and transplanted based on risk profile High risk (HR): African‐Americans; PRA ≥ 20%; re‐transplant Low risk (LR): non‐African‐Americans; PRA < 20%, primary transplant Age: Adults Number (Bas‐LR/CIH‐LR/CIH‐HR/Thymo‐HR): 474 (171/164/70/69)
Interventions	Treatment group Basiliximab: 2 doses (20 mg) days 0‐4 Control group (CIH‐LR/CIH‐HR/Thymo‐HR) Other antibodies (HR and LR patients given alemtuzumab) Alemtuzumab (CIH): 30 mg, day 0 Thymoglobulin: 15 mg/kg/d, days 0‐4 Baseline immunosuppression TAC: NS MMF: NS Steroids: 1 g prior to discharge
Outcomes	Mortality Graft loss Acute rejection Delayed graft function Infection/CMV Malignancy
Notes	Groups 2 and 3 and 4 combined for comparison IL2R versus other antibody 1 year follow‐up
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated "randomized" no further information provided
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) Objective outcomes	Unclear risk	Not stated
Blinding (performance bias and detection bias) Subjective outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	High risk	All patient numbers listed under parameters in results table, however dichotomous results presented as percentages and no SD for continuous outcomes
Selective reporting (reporting bias)	High risk	Primary outcomes only reported as percentages
Other bias	High risk	Funding source not stated, 1 author employee of the pharmaceutical company Astellas Pharma U.S. Abstract only data available